Article Versions Notes

Bertin L, Barberio B, Gubbiotti A, Bertani L, Costa F, Ceccarelli L, Visaggi P, Bodini G, Pasta A, Sablich R, et al. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease. Journal of Clinical Medicine. 2024; 13(6):1539. https://doi.org/10.3390/jcm13061539

Bertin, Luisa, Brigida Barberio, Alessandro Gubbiotti, Lorenzo Bertani, Francesco Costa, Linda Ceccarelli, Pierfrancesco Visaggi, Giorgia Bodini, Andrea Pasta, Renato Sablich, and et al. 2024. "Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease" Journal of Clinical Medicine 13, no. 6: 1539. https://doi.org/10.3390/jcm13061539

Bertin, L., Barberio, B., Gubbiotti, A., Bertani, L., Costa, F., Ceccarelli, L., Visaggi, P., Bodini, G., Pasta, A., Sablich, R., Urbano, M. T., Ferronato, A., Buda, A., De Bona, M., Del Corso, G., Massano, A., Angriman, I., Scarpa, M., Zingone, F., & Savarino, E. V. (2024). Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease. Journal of Clinical Medicine, 13(6), 1539. https://doi.org/10.3390/jcm13061539